Cancer Vaccine Institute News

KING 5 Highlights CVI’s Progress Toward COLOVAC - A Colon Cancer Prevention Vaccine

Last week, KING 5 News featured ongoing research at the Cancer Vaccine Institute (CVI) to develop COLOVAC , a preventive vaccine designed to stop colon cancer before it starts. The segment included interviews with CVI Director Dr. Nora Disis and Becky Bruhn, a Seattle resident whose recent cancerous polyp illustrates the importance of early detection and need for new prevention tools. Colon cancer remains one of the leading causes of cancer death in the United States, and rat

Sarah White

Mar 23

DNA-based HER2 vaccine has stronger anti-cancer immune response compared to HER2 peptide vaccines

Dr. Ying Liu presented this study at the 2025 San Antonio Breast Cancer Symposium At the UW Cancer Vaccine Institute, we are working to develop vaccines that train the immune system to recognize and eliminate cancer. At the 2025 San Antonio Breast Cancer Symposium, we shared new data comparing two of our HER2-targeted therapeutic vaccine platforms for people with advanced HER2-positive breast cancer. About 20% of all breast cancers overexpress the HER2 protein, which can make

Sarah White

Feb 17

CVI's WOKVAC, a HER2-directed vaccine, shows promising results in multicenter clinical trial

The Cancer Vaccine Institute (CVI) was excited to share new results from a multi-center clinical trial led by Moffitt Cancer Center at the 2025 San Antonio Breast Cancer Symposium. These results offer encouraging evidence for WOKVAC, a HER2-targeted DNA vaccine developed here at the CVI. In this study, Moffitt and collaborating sites evaluated whether HER2 vaccination could help prevent recurrence in patients at especially high risk, including individuals who still have invas

Sarah White

Feb 17